Magnetic Granules Hold Pledge As Potential Preeclampsia Tx



[ad_1]

Magnetic beads may have the potential to treat a molecule in the blood seen in high abundance in pregnant women with preeclampsia, according to an in vitro proof of concept study.

Working with blood samples from women with preeclampsia, researchers have been able to substantially reduce levels of soluble endothelial growth factor (sFlt-1), which is responsible for both angiogenic imbalance and endothelial dysfunction, said Vassilis Tsatsaris, MD, PhD , of Cochin Hospital. Paris in Hypertension.

They observed that during preeclampsia, a "massive amount" of sFlt-1 is released by the placenta, which inhibits both vascular endothelial growth factor (VEGF) and placental growth factor (PLGF), which are not only essential to the endothelium, or cells lining the inner surface of blood vessels and lymphatic vessels, but explain endothelial dysfunction during preeclampsia.

"This was a proof-of-concept study and our approach aims to restore the physiological levels of angiogenic factors," Tsatsaris said in a statement.

The authors said that their goal was to develop and provide a proof of concept of a selective and competitive apheresis – or to separate a particular constituent from the blood. In this case, it reduced sFlt-1 and increased free PlGF "to restore the physiological angiogenic balance in the maternal circulation."

The researchers grafted magnetic beads with sFlt-1 molecules, which compete with PlGF. So, to "increase capture of sFlt-1 and optimize equilibrium displacement," they also used VEGF as a competitive binder – which has a more than 10-fold greater affinity for sFlt-1 than PlGF, said the researchers. authors.

"This competitive biomimetic binding approach captures circulating sFlt-1 while releasing endogenous PlGF, thereby increasing the bioavailability of PlGF and potentiating its proangiogenic effects on maternal endothelial function," they wrote.

To test this approach in humans, the researchers used plasma samples from pregnant women with preeclampsia. They found a 40% reduction in sFlt-1 and an increase in free PlgF concentration from one-sixth to more than double in all samples tested, the authors said.

"So our microfluidic V-bead system decreased the sFlt-1 / PlGF ratio in plasma samples by 63% on average," they wrote.

The authors observed that the flow rates and fluid volumes used in their study are not compatible with the application in pregnant women but that the device could be of interest for a proof of concept in animal models. They said their next steps with this research include the development of apheresis columns based on the binder-based approach, "and usable in vivo with an animal model."

The study was funded by the National Agency for Research, the Pierre Gilles de Gennes Institute and the PremUP Foundation.

Trapiella-Alfonso did not reveal relevant relations with the industry. Co-authors reported the support of the Ecole Normale Supérieure and the Fondation pour la Recherche Médicale.

2019-05-13T17: 30: 00-0400

[ad_2]

Source link